Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells

被引：0
|
作者：
M Bar-Natan
E A Nelson
S R Walker
Y Kuang
R J Distel
D A Frank
机构：
[1] Dana-Farber Cancer Institute,Department of Medical Oncology
[2] Brigham and Women's Hospital,Departments of Medicine
[3] and Harvard Medical School,undefined
[4] Translational Research Laboratory,undefined
[5] The Center for Clinical and Translational Research,undefined
[6] Dana-Farber Cancer Institute,undefined
来源：
Leukemia | 2012年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1407 / 1410
页数：3
相关论文
共 50 条
  • [1] Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells
    Bar-Natan, M.
    Nelson, E. A.
    Walker, S. R.
    Kuang, Y.
    Distel, R. J.
    Frank, D. A.
    LEUKEMIA, 2012, 26 (06) : 1407 - 1410
  • [2] Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells.
    Bar-Natan, Michal
    Nelson, Erik A.
    Walker, Sarah R.
    Barrett, Rosemary
    Frank, David A.
    BLOOD, 2009, 114 (22) : 756 - 756
  • [3] REGULATORY NETWORKS OF JAK2/STAT5 PATHWAY ACTIVITY IN MYELOPROLIFERATIVE NEOPLASIA CELL LINES
    Salas Cintora, E. M.
    Garcia-Barchino, M. J.
    Vizmanos, J. L.
    Novo, F. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 400 - 400
  • [4] In vitro interaction between STAT5 and JAK2;: dependence upon phosphorylation status of STAT5 and JAK2
    Flores-Morales, A
    Pircher, TJ
    Silvennoinen, O
    Gustafsson, JÅ
    Sanchez-Gomez, M
    Norstedt, G
    Haldosén, LA
    Wood, TJJ
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1998, 138 (1-2) : 1 - 10
  • [5] Effect of GJIC modulation on Jak2/STAT5 in mammary cells in vitro
    Talhouk, RS
    Ismail, A
    Zeytouni, T
    El-Sabban, ME
    MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 491A - 491A
  • [6] JAK2/STAT5 signaling in the lipopolysaccharide (LPS)-induced inhibition of osteoblast differentiation
    Wu, Hao
    Liu, Guanghui
    Yu, Bin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (11): : 11119 - 11128
  • [7] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
    Hexner, Elizabeth O.
    Serdikoff, Cynthia
    Jan, Mahfuza
    Swider, Cezary R.
    Robinson, Candy
    Yang, Shi
    Angeles, Thelma
    Emerson, Stephen G.
    Carroll, Martin
    Ruggeri, Bruce
    Dobrzanski, Pawel
    BLOOD, 2008, 111 (12) : 5663 - 5671
  • [8] CEP-701 is a JAK2 inhibitor which attenuates JAK2/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders.
    Dobrzanski, Pawel
    Hexner, Elizabeth
    Serdikoff, Cynthia
    Jan, Mahfuza
    Swider, Cezary
    Robinson, Candy
    Yang, Shi
    Angeles, Thelma
    Emerson, Stephen G.
    Carroll, Martin
    Ruggeri, Bruce
    BLOOD, 2006, 108 (11) : 1026A - 1026A
  • [9] MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling
    K Kollmann
    J Nangalia
    W Warsch
    H Quentmeier
    A Bench
    E Boyd
    M Scott
    H G Drexler
    A R Green
    Leukemia, 2015, 29 : 494 - 497
  • [10] MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling
    Kollmann, K.
    Nangalia, J.
    Warsch, W.
    Quentmeier, H.
    Bench, A.
    Boyd, E.
    Scott, M.
    Drexler, H. G.
    Green, A. R.
    LEUKEMIA, 2015, 29 (02) : 494 - 497
12345